Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.60 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027127 | 0.87 | PIK3CA (0.68) | PIK3CAPIK3CBPIK3CGATR | |
| SCHEMBL13241456 | 0.87 | PIK3CA (0.66) | PIK3CAPIK3CBPIK3CGRAD52ACHE | |
| SCHEMBL370181 | 0.87 | PIK3CA (0.66) | PIK3CAPIK3CBPIK3CGATRRAD52 | |
| SCHEMBL13220255 | 0.86 | PIK3CA (0.79) | PIK3CAPIK3CBPIK3CGATRACHE | |
| SCHEMBL3037741 | 0.85 | PIK3CA (0.62) | PIK3CAPIK3CBPIK3CGATRRAD52 | |
| SCHEMBL3040376 | 0.85 | PIK3CA (0.64) | PIK3CAPIK3CBPIK3CGATRRAD52 | |
| SCHEMBL3037754 | 0.83 | PIK3CA (0.60) | PIK3CAPIK3CBPIK3CGRAD52ACHE | |
| SCHEMBL1026996 | 0.81 | PIK3CA (0.68) | PIK3CAPIK3CBPIK3CGATR | |
| SCHEMBL3029737 | 0.79 | PIK3CA (0.62) | PIK3CAPIK3CBPIK3CGRAD52ACHE | |
| SCHEMBL3596640 | 0.77 | ATR (0.50) | PIK3CAPIK3CBPIK3CGATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210646-A1 | 2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-19 | — | — | US | claimed |
| US-20100210646-A1 | 2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-19 | — | — | US | disclosed |
| US-20100210646-A1 | 2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-19 | — | — | US | disclosed |
| WO-2008125835-A1 | 2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210646-A1 | 2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CB 3/4885PIK3CG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.